

# Giovanni Davi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3853268/giovanni-davi-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95  
papers

7,581  
citations

42  
h-index

86  
g-index

99  
ext. papers

8,312  
ext. citations

7.1  
avg, IF

5.79  
L-index

#	Paper	IF	Citations
95	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 651-660	3.7	9
94	Carotid plaque detection improves the predictive value of CHADS-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , <b>2017</b> , 231, 143-149	3.7	16
93	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 387-406	3.7	40
92	Platelets and Diabetes <b>2017</b> , 1225-1238		1
91	Effects of Liraglutide on Weight Loss, Fat Distribution, and $\beta$ Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. <i>Diabetes Care</i> , <b>2017</b> , 40, 1556-1564	14.6	45
90	Oxidant stress as a major determinant of platelet activation in invasive breast cancer. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 696-704	7.5	16
89	Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. <i>Circulation Journal</i> , <b>2016</b> , 80, 502-11	2.9	10
88	Microparticles as new markers of cardiovascular risk in diabetes and beyond. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 220-34	7	55
87	Arterial stiffness and sedentary lifestyle: Role of oxidative stress. <i>Vascular Pharmacology</i> , <b>2016</b> , 79, 1-5	5.9	31
86	Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF- $\alpha$ treatment. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 486-95	7	24
85	High serum CXCL10 in <i>Rickettsia conorii</i> infection is endothelial cell mediated subsequent to whole blood activation. <i>Cytokine</i> , <b>2016</b> , 83, 269-274	4	2
84	Correlation between Migraine Severity and Cholesterol Levels. <i>Pain Practice</i> , <b>2015</b> , 15, 662-70	3	24
83	Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. <i>Atherosclerosis</i> , <b>2015</b> , 238, 350-5	3.1	23
82	MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 3592-600	5.4	33
81	Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. <i>Vascular Pharmacology</i> , <b>2015</b> , 72, 16-24	5.9	17
80	Platelets and diabetes mellitus. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2015</b> , 120, 28-39	3.7	60
79	Oxidative stress in chronic vascular disease: From prediction to prevention. <i>Vascular Pharmacology</i> , <b>2015</b> , 74, 23-37	5.9	94

78	Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 876-82	7	12
77	Thromboxane-dependent platelet activation after gastric banding for obesity. <i>JAMA Surgery</i> , <b>2015</b> , 150, 179-80	5.4	2
76	Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. <i>Free Radical Biology and Medicine</i> , <b>2015</b> , 80, 101-10	7.8	40
75	Increased expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental <i>Rickettsia conorii</i> infection. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 70	4	5
74	Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis. <i>European Journal of Dermatology</i> , <b>2014</b> , 24, 133-5	0.8	8
73	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A state-of-the-art paper. <i>European Heart Journal</i> , <b>2014</b> , 35, 2213-23b	9.5	55
72	Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. <i>Haematologica</i> , <b>2014</b> , 99, 1638-44	6.6	17
71	Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3,	6	40
70	Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3,	6	17
69	Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy. <i>Oncologist</i> , <b>2014</b> , 19, 562-7	5.7	7
68	Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000063	6	21
67	Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1232-40	7	24
66	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 1220-30	15.4	171
65	A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction. <i>Journal of Immunological Methods</i> , <b>2012</b> , 380, 16-22	2.5	49
64	Diabetes mellitus and thrombosis. <i>Thrombosis Research</i> , <b>2012</b> , 129, 371-7	8.2	141
63	Thromboxane receptors antagonists and/or synthase inhibitors. <i>Handbook of Experimental Pharmacology</i> , <b>2012</b> , 261-86	3.2	41
62	Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. <i>Antioxidants and Redox Signaling</i> , <b>2012</b> , 17, 1447-85	8.4	54
61	Cardiovascular risk and dietary sugar intake: is the link so sweet?. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 313-22	3.7	12

60	Variability in the response to antiplatelet treatment in diabetes mellitus. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2012</b> , 98, 48-55	3.7	6
59	Platelets, oxidative stress and preservation of the vascular endothelium: is it a matter of fat?. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 199-201	3.7	2
58	Platelet activation in obesity and metabolic syndrome. <i>Obesity Reviews</i> , <b>2012</b> , 13, 27-42	10.6	137
57	Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. <i>Free Radical Biology and Medicine</i> , <b>2012</b> , 52, 1318-24	7.8	42
56	Obesity-driven inflammation and colorectal cancer. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 5837-53	4.3	31
55	Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, E1726-30	5.6	37
54	Biomarkers of platelet activation in acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1109-23	7	69
53	A complex interaction between Rickettsia conorii and Dickkopf-1--potential role in immune evasion mechanisms in endothelial cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e43638	3.7	14
52	Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. <i>Atherosclerosis</i> , <b>2011</b> , 214, 122-8	3.1	64
51	Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 321-9	7	26
50	TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6, 203-12	3.7	22
49	Determinants of increased cardiovascular disease in obesity and metabolic syndrome. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 5267-80	4.3	48
48	Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects. <i>Stress</i> , <b>2011</b> , 14, 282-9	3	18
47	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. <i>FASEB Journal</i> , <b>2010</b> , 24, 3970-80	0.9	63
46	Soluble CD40L in Mediterranean Spotted Fever: relation to oxidative stress and platelet activation. <i>Thrombosis Research</i> , <b>2010</b> , 125, 362-4	8.2	2
45	Nutraceuticals in diabetes and metabolic syndrome. <i>Cardiovascular Therapeutics</i> , <b>2010</b> , 28, 216-26	3.3	106
44	The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. <i>Blood</i> , <b>2010</b> , 115, 1054-61	2.2	83
43	Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. <i>Free Radical Biology and Medicine</i> , <b>2010</b> , 49, 857-64	7.8	18

42	CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2009</b> , 16, 707-13	4	49
41	Soluble forms of RAGE in human diseases: clinical and therapeutical implications. <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 940-52	4.3	140
40	Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 27, 348-51	5.1	14
39	Relationship between factor XII deficiency and thrombosis: the debate is still open?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 27, 456-7	5.1	1
38	Soluble forms of RAGE in internal medicine. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 389-401	3.7	143
37	Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever. <i>Journal of Infection</i> , <b>2009</b> , 58, 68-75	18.9	26
36	Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. <i>Thrombosis Research</i> , <b>2009</b> , 124, 96-100	8.2	32
35	Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 667-77	15.1	193
34	Oxidative-induced membrane damage in diabetes lymphocytes: effects on intracellular Ca(2+) homeostasis. <i>Free Radical Research</i> , <b>2009</b> , 43, 138-48	4	26
33	Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 687-690	7	29
32	Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. <i>Blood</i> , <b>2008</b> , 112, 1085-90	2.2	25
31	Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2008</b> , 24, 231-7	7.5	51
30	Homocysteine modulates the CD40/CD40L system. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 2182-90	15.1	19
29	Soluble RAGE in type 2 diabetes: association with oxidative stress. <i>Free Radical Biology and Medicine</i> , <b>2007</b> , 43, 511-8	7.8	113
28	Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. <i>Free Radical Biology and Medicine</i> , <b>2007</b> , 43, 1255-62	7.8	97
27	Determinants of platelet activation in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2007</b> , 28, 336-42	5.6	62
26	Platelet activation and atherothrombosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2482-94	59.2	1573
25	Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 391-7	15.1	91

24	Insulin resistance as a determinant of platelet activation in obese women. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 2531-8	15.1	98
23	Isoprostane formation and inhibition in atherothrombosis. <i>Current Opinion in Pharmacology</i> , <b>2005</b> , 5, 198-203	5.1	63
22	Lipid peroxidation in diabetes mellitus. <i>Antioxidants and Redox Signaling</i> , <b>2005</b> , 7, 256-68	8.4	248
21	Oxidant stress and platelet activation in hypercholesterolemia. <i>Antioxidants and Redox Signaling</i> , <b>2004</b> , 6, 747-56	8.4	43
20	Inflammation, insulin resistance, and obesity. <i>Current Atherosclerosis Reports</i> , <b>2004</b> , 6, 424-31	6	116
19	Determinants of F2-isoprostane biosynthesis and inhibition in man. <i>Chemistry and Physics of Lipids</i> , <b>2004</b> , 128, 149-63	3.7	76
18	Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 5321-6	5.6	99
17	Physical exercise increases urinary excretion of lipoxin A4 and related compounds. <i>Journal of Applied Physiology</i> , <b>2003</b> , 94, 2237-40	3.7	47
16	Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1013-20	15.1	207
15	Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. <i>Circulation</i> , <b>2003</b> , 107, 3199-203	16.7	119
14	Platelet activation in obese women: role of inflammation and oxidant stress. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 2008-14	27.4	406
13	Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. <i>Circulation</i> , <b>2002</b> , 106, 399-402	16.7	195
12	Endothelial Perturbation in Cystic Fibrosis. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 86, 1363-1367	7	26
11	In vivo lipid peroxidation and platelet activation in cystic fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 162, 1195-201	10.2	77
10	Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 2689-97		29
9	In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 3230-5	9.4	320
8	Platelet Activation Markers in Patients with Peripheral Arterial Disease. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 1434-1437	7	33
7	Influence of Metabolic Control on Thromboxane Biosynthesis and Plasma Plasminogen Activator Inhibitor Type-1 in Non-insulin-dependent Diabetes mellitus. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 76, 034-037	7	14

6	Demonstration of Rickettsia Conorii-Induced Coagulative and Platelet Activation in vivo in Patients with Mediterranean Spotted Fever. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 631-634	7	27
5	Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 1015-1019	7	25
4	Antiplatelet agents in the prevention of diabetic vascular complications. <i>Diabetes/metabolism Reviews</i> , <b>1993</b> , 9, 177-88		15
3	Thrombin-antithrombin III complexes in type II diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>1992</b> , 6, 7-11	3.2	25
2	Thromboxane biosynthesis and platelet function in type II diabetes mellitus. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 1769-74	59.2	487
1	Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>1989</b> , 992, 66-70	4	83